ArticleJournal of pediatric gastroenterology and nutrition2026
Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesMethotrexate (MTX) is frequently prescribed in paediatric inflammatory bowel disease (IBD), with routine laboratory monitoring to detect adverse events (AEs), such as hepatotoxicity and myelotoxicity. However, data on the incidence and predictors of these AEs remain limited. This study aimed to assess the incidence of MTX-induced AEs in paediatric IBD, and to identify associated factors.
methodsWe conducted a retrospective monocentre cohort study, including paediatric IBD patients initiating MTX at Amsterdam University Medical Centre between 2010 and 2023. We collected demographic, disease and therapy data, and laboratory results. We evaluated biochemical toxicity (hepatotoxicity or myelotoxicity) and nausea and vomiting, classifying AE severity using common terminology criteria for AEs.
resultsA total of 207 paediatric IBD patients (181 Crohn's disease, 17 ulcerative colitis, 9 IBD-unclassified) starting MTX therapy were included, 114 of whom used MTX as immunomodulator alongside a biological drug. Hepatotoxicity occurred in 41% (61% grade 1, 12% grade 3), and myelotoxicity in 21% (81% mild, 0 severe cases). Nausea was reported in 46%. MTX was discontinued due to an AE in 60 cases (38%), including 27 following hepatotoxicity, 4 following myelotoxicity, and 27 following nausea. Male sex (relative risk [RR] 1.4, p = 0.003) and lower MTX dose (RR 0.9, p = 0.003) predicted biochemical toxicity. Nausea was associated with male sex (RR 1.7, p = 0.002), oral administration (RR 0.5 for subcutaneous route, p < 0.001), and higher MTX dose (RR 1.1, p = 0.005).
conclusionsMTX-induced AEs are common but rarely severe in paediatric IBD. Male sex, MTX dosage, and oral administration significantly influence the risk of MTX-induced AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.